Andrew McKee shares an article on the latest developments in Ulcerative Colitis.  Many of our clients are pursuing groundbreaking therapies in disease areas with high unmet medical needs, giving our firm the chance to become intimately familiar with some of the most exciting areas in drug development.  One disease area that is receiving a lot of attention is Inflammatory Bowel Disease (IBD), where the disease burden and the need for novel, efficacious therapeutics remain high.  Below, we’ll share our thoughts…

Umbrex is pleased to welcome Andrew McKee with Headland Strategy Group. Andrew has 15 years’ experience in biotechnology, pharmaceuticals, diagnostics, and other healthcare sectors. In his health care work, he specializes in consulting projects for healthcare executives that combine disruptive growth strategy expertise (e.g., disease area strategy, pipeline marketing/commercial evaluations, novel disruptive technologies) with distinctive consulting offerings (e.g., strategic decision-making workshop design and facilitation; qualitative market research with thought leaders). These projects necessarily require Andrew and his team to be…